Spatially resolved transcriptomics identified distinct tumor-stroma crosstalk
networks associated with chemoresistance in ovarian cancer
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Introduction
More than 14,000 patients in the United States die of ovarian
cancer each year, making this cancer the fifth leading, and
therefore most lethal, cause of cancer death among women in the
United States. High grade serous ovarian carcinoma (HGSC),
which accounts for 70% of all cases, is the most aggressive form
of ovarian cancer. It characteristically arises from fallopian
epithelial tissue and spreads to multiple locations within the
abdomen before it is diagnosed at stage 3 or 4. At this point,
clinical intervention is limited, resulting in a 10-year survival rate
of a devastating less than 20%. Treatment options currently
consist of cytoreductive surgery before or followed by platinumand taxane-based combination chemotherapy. A majority
of patients respond to this first line treatment and thus are in
possession of chemosensitive tumors; however, in a subset
of patients, tumors recur within 6 months after the last cycle of
treatment developing chemoresistance.
Additionally, ovarian cancer progression is often dictated by
strategically located activity of cells and proteins in the tumor
microenvironment (TME). Consisting of fibroblasts, extracellular
matrix proteins, endothelial cells, lymphocytic infiltrates, and
cancer cells, the TME allows for sustenance of the tumor through
crosstalk signaling networks established between cancer and
stromal cells. The TME directly affects chemoresistance and
patient survival by reducing the positive effects of
chemotherapeutic drugs by hindering drug absorption.
Recent discoveries suggest the existence of biological
differences in advanced stage HGSC chemoresistant and
chemosenstive tumors. Substantial efforts have been made to
develop gene expression-based molecular signatures and
biomarkers from these cells to predict chemoresistance in
HGSC. Spatial transcriptomics (ST) is a cutting-edge technology
capable of providing a rich spatial context to gene expression
by generating thousands of spatially resolved transcriptomes on a
single tissue section with a resolution of 10-50 cells. Recently, ST
has been used to provide meaningful biological insights based on
spatial proximity in complicated cancers such as pancreatic
cancer. However, a transcriptome-based signature that can
predict chemoresistance in HGSC is still lacking.
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Results

Figure 1. Tumor ST clusters assigned by the Multimodal intersection analysis (MIA) matched histology images. After alignment of fastq file using Cell
Ranger (10x Genomics), an average of 3500 distinct genes were detected in each spot. Each sample was then loaded into R Seurat package and normalized by
SCTransform. Phenograph clustering was then performed by using the first 10 dimensions of PCA. Genes with significantly higher expression in each ST
cluster relative to the others were identified (P<0.01, Wilcoxon Rank Sum test and log_FoldChange>0). A. scRNAseq data from Shih et al. PLoS One. 2018
were analyzed and used to define gene sets: for each cell type, genes whose expression was statistically higher in the cells annotated to that cell type in
comparison with expression in the remaining cells were identified (P<10−5, Wilcoxon Rank Sum test). B. With the gene sets extracted across the scRNA-seq
and ST modalities, the overlap between each pair of cell type-specific and region-specific gene sets was computed by MIA. A hypergeometric test was
performed to assess significant enrichment (Enrichment threshold P<10−10). e.g. Tumor clusters were assigned if the enrichment p-value of any of the epithelial
cell types Ep_1, Ep_2, and Ep_3 in that cluster was lower than 10−10. Fibroblast clusters were assigned similarly. Clusters other than tumor and fibroblast were
assigned as non-fibroblastic stroma. C. Assigned clusters overlaid on H&E images. Colors indicated the clustering assignments. Tumor clusters matched the
morphology of tumor regions on H&E images.

Figure 2: Characterization of tumor and stroma subclusters helped to elucidate the heterogeneity of these cellular
compartments and validation of stroma subclusters by multiplex immunofluorescence (mIF). A-B. Multiple rounds of
subclustering highlighted the heterogenicity in the HGSC tumors and TME. Differential gene expression analysis for each subcluster
revealed markers useful to discriminate chemoresistant from chemosensitive tumors. Periostin (POSTN) is a matricellular protein that
is expressed by fibroblasts. It has a key function in organizing the extracellular matrix, and high expression in the stroma has been
shown to correlate with lower overall survival and greater treatment resistance. Gonzalez L. et al. Frontiers in Oncology (2018).
POSTN recruits Wnt ligands. Malanchi I. et al. Nature (2011). CD36 is a membrane glycoprotein receptor that is associated with tumor
biology by playing a roll in antigen presentation, inflammation, angiogenesis and cell adhesion. Ladanyi A. et al. Oncogene (2018).
Furthermore, it enhances lipid uptake and FA oxidation and is associated with tumor immune tolerance. By binding to TSP-1, CD36
induces apoptosis and blocks the VEGFR-2 pathway. Wang J. et al. Theragnostics (2019). CDK1 is a commonly known cell cycle
regulator whose abnormal activation results in high proliferation and apoptosis prevention of ovarian cancer cells. Zhang R. et al.
Journal of Ovarian Research (2017). LGR5 modulates Wnt/beta-catenin signaling, which regulates proliferation and differentiation of
adult stem cells. It is able to induce EMT, thereby the expression of this molecule is associated with distant metastasis. Liu W. et al.
Cancer Medicine (2018). C. mIF was used to validate the expression of Periostin and CD36 in stroma subsclusters.

Conclusions
•
•

•

New class of biomarkers based on spatial intratumoral heterogeneity and spatially
resolved transcriptomic analyses can be used to develop predictive models
for chemoresistance.
Novel therapeutic strategies can be developed to target not only tumor and stromal cells,
but also the ligand-receptor crosstalk networks established between cancer and stromal
cells, which may result in improved survival rates for HGSC patients
with chemoresistant disease.
Validation of optimized mIF antibody panels including Periostin-CD36-COL1A1,
APOE-LRP5-COL1A1 and THBS2-CD47-COL1A1 in a larger cohort of
chemosensitive and chemoresistant tumor samples is ongoing.

Figure 3: Crosstalk signaling network analysis and validation of ligand-receptor pairs associated with che moresistance by mIF. A. H&E image of representative refractory sample with overlaid cluster assignment. B. Expression map of selected spots from tumor cluster c2 (orange) and stroma
cluster c0 (grey) and used for cross-talk signaling network analysis (receptor in tumor, ligand in stroma). Red lines indicates tumor areas. C. Top 6 ligand-receptor pair selected after cross-talk signaling network analysis in refractory and chemosensitive samples. D. Multiplex IF image of a
representative chemoresistant sample . E. Tissue segmentation of representative sample using Visiopharm analysis software to identify tumor (green), stroma (blue) and tumor/stroma boundary areas. F. ST RNA expression maps of LRP5 receptor and APOE ligand to validate their higher expression in
tumor and stroma, respectively. G. Multiplex IF image highlighting presence of LRP5 receptor in the tumor and APOE ligand in the stroma. COL1A1 was used to define stroma areas. H-I. Graph depicting the mean intensity of LRP5 (H) and APOE (I) in the tumor, stroma, and tumor/stroma boundary.
J. Graph correlating the mean intensity of LRP5 and APOE at the tumor stroma boundary resulting in a Pearson correlation value of 0.616 (p=0.01). The lower Pearson correlation coefficients for the tumor and stroma regions emphasize a significant association between ligand and receptor at the tumor
stroma interface. K. ST RNA expression maps with CD47 receptor and THBS2 ligand to validate their higher expression in tumor and stroma, respectively. L. Multiplex IF image highlighting presence of CD47 receptor in the tumor and THBS2 ligand in the stroma. COL1A1 was used to define stroma
areas. M-N. Graph depicting the mean intensity of CD47 (M) and THBS2 (N) in the tumor, stroma, and tumor/stroma boundary. O. Graph correlating the mean intensity of THBS2 and CD47 at the tumor stroma boundary resulting in a Pearson correlation value of 0.621 (p=0.01).

